Loading...
A randomized trial showed amitriptyline, pregabalin, and duloxetine to have equal efficacy in treating patients with painful diabetic neuropathy, and two-drug regimens boosted response rates somewhat. Still, half of patients didn't have clinically important responses, and drug side effects were frequent — illustrating the challenges in managing this common condition (NEJM JW Gen Med Nov 1 2022 and Lancet 2022; 400:680).
In placebo-controlled trials involving adolescents with obesity, both semaglutide and phentermine/topiramate lowered weight substantially during 1 year of treatment. Neither of these drugs is FDA-approved for weight loss in adolescents. If approval is granted, clinicians' views…